3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]-1-(3-methyl-4-hydroxyphenyl)propan-1-one | 500581-76-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]-1-(3-methyl-4-hydroxyphenyl)propan-1-one
• 英文别名: 1-(4-Hydroxy-3-methylphenyl)-3-[4-isopropyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propan-1-one；1-(4-hydroxy-3-methylphenyl)-3-[4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-1-one
• CAS: 500581-76-0
• 化学式: C₂₃H₂₂F₃NO₂S
• 分子量: 433.494
• InChiKey: PVFRDBDFZUEIMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]-1-(3-methyl-4-hydroxyphenyl)propan-1-one 、 2-溴丙酸乙酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 20.0h， 以100%的产率得到ethyl 2-[4-[3-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]propionyl]-2-methylphenoxy]propionate
  参考文献：
  名称：

  ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA

  摘要：

  公开号：

  EP1424330B1
• 作为产物：
  描述：

  3-(4-benzyloxy-3-methyl-phenyl)-3-oxo-propionic acid ethyl ester 、 5-iodomethyl-4-isopropyl-2-(4-trifluoromethyl)phenylthiazole 在 sodium hydride 、 盐酸 作用下， 以 四氢呋喃 、 水 、 溶剂黄146 为溶剂， 反应 31.0h， 以73%的产率得到3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]-1-(3-methyl-4-hydroxyphenyl)propan-1-one
  参考文献：
  名称：

  ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA

  摘要：

  公开号：

  EP1424330B1

文献信息

• Activator of peroxisome proliferator-activated receptor
  申请人：Sakuma Shogo

  公开号：US20050054674A1

  公开（公告）日：2005-03-10

  A compound represented by the following general formula (I): (wherein R 1 represents phenyl, etc. which can have substituents selected from the group consisting of C 1-8 alkyl, C 1-8 alkyl having halogen, halogen, hydroxyl, etc.; R 2 represents C 1-8 alkyl, etc.; A represents oxygen, sulfur, etc.; X represents C 1-8 alkylene chain, etc.; Y represents C(═O), CH═CH, etc.; R 3 , R 4 , and R 5 each represents hydrogen, C 1-8 alkyl, etc.; B represents CH or nitrogen; Z represents oxygen or sulfur; R 6 and R 7 each represents hydrogen, C 1-8 alkyl, etc.; and R 8 represents hydrogen or C 1-8 alkyl; provided that at least one of R 3 , R 4 , and R 5 is not hydrogen) or a salt of the compound; and a PPAR-δ activator which contains the compound or salt as the active ingredient.

  以下是一种由下列通式(I)表示的化合物：（其中R1代表苯基等，可以具有选择自C1-8烷基，具有卤素的C1-8烷基，卤素，羟基等的取代基; R2代表C1-8烷基等; A代表氧，硫等; X代表C1-8烷基链等; Y代表C（═O），CH═CH等; R3，R4和R5各代表氢，C1-8烷基等; B代表CH或氮; Z代表氧或硫; R6和R7各代表氢，C1-8烷基等; R8代表氢或C1-8烷基; 前提是R3、R4和R5中至少有一个不是氢）或该化合物的盐；以及包含该化合物或盐作为活性成分的PPAR-δ激动剂。
• Activator of peroxisome proliferator-activated receptor delta
  申请人：Sakuma Shogo

  公开号：US20080009525A1

  公开（公告）日：2008-01-10

  A compound represented by the following general formula (I): (wherein R 1 represents phenyl, etc. which can have substituents selected from the group consisting of C 1-8 alkyl, C 1-8 alkyl having halogen, halogen, hydroxyl, etc.; R 2 represents C 1-8 alkyl, etc.; A represents oxygen, sulfur, etc.; X represents C 1-8 alkylene chain, etc.; Y represents C(═O), CH═CH, etc.; R 3 , R 4 , and R 5 each represents hydrogen, C 1-8 alkyl, etc.; B represents CH or nitrogen; Z represents oxygen or sulfur; R 6 and R 7 each represents hydrogen, C 1-8 alkyl, etc.; and R 8 represents hydrogen or C 1-8 alkyl; provided that at least one of R 3 , R 4 , and R 5 is not hydrogen) or a salt of the compound; and a PPAR-δ activator which contains the compound or salt as the active ingredient.

  以下是通式(I)所代表的化合物（其中R1代表苯基等，可具有选自C1-8烷基，带有卤素的C1-8烷基，卤素，羟基等取代基；R2代表C1-8烷基等；A代表氧，硫等；X代表C1-8亚烷基链等；Y代表C（═O），CH═CH等；R3，R4和R5各代表氢，C1-8烷基等；B代表CH或氮；Z代表氧或硫；R6和R7各代表氢，C1-8烷基等；R8代表氢或C1-8烷基；但至少其中之一的R3，R4和R5不是氢）或该化合物的盐；以及以该化合物或盐作为活性成分的PPAR-δ激动剂。
• Activator for peroxisome proliferator-activated receptor delta
  申请人：Sakuma Shogo

  公开号：US20080009631A1

  公开（公告）日：2008-01-10

  A compound represented by the following general formula (I): (wherein R 1 represents phenyl, etc. which can have substituents selected from the group consisting of C 1-8 alkyl, C 1-8 alkyl having halogen, halogen, hydroxyl, etc.; R 2 represents C 1-8 alkyl, etc.; A represents oxygen, sulfur, etc.; X represents C 1-8 alkylene chain, etc.; Y represents C(═O), CH═CH, etc.; R 3 , R 4 , and R 5 each represents hydrogen, C 1-8 alkyl, etc.; B represents CH or nitrogen; Z represents oxygen or sulfur; R 6 and R 7 each represents hydrogen, C 1-8 alkyl, etc.; and R 8 represents hydrogen or C 1-8 alkyl; provided that at least one of R 3 , R 4 , and R 5 is not hydrogen) or a salt of the compound; and a PPAR-δ activator which contains the compound or salt as the active ingredient.

  以下是一种由下列通式（I）表示的化合物：（其中，R1代表苯基等，可以具有选自C1-8烷基，具有卤素的C1-8烷基，卤素，羟基等的取代基; R2代表C1-8烷基等; A代表氧，硫等; X代表C1-8烷基链等; Y代表C(═O)，CH═CH等; R3、R4和R5各代表氢，C1-8烷基等; B代表CH或氮; Z代表氧或硫; R6和R7各代表氢，C1-8烷基等; R8代表氢或C1-8烷基; 前提是R3、R4和R5中至少有一个不是氢）或该化合物的盐;以及包含该化合物或盐作为活性成分的PPAR-δ激动剂。
• Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
  申请人：Barbaras Ronald

  公开号：US20110092517A1

  公开（公告）日：2011-04-21

  Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In one embodiment, the disease or condition is selected from myopathy, inflammatory vascular diseases, Parkinson's and Alzheimer's diseases, systemic inflammatory disorders, renal ischemia, inflammatory rheumatic disorders, and inflammatory diseases of the lung. In another embodiment, methods for increasing oxidative muscle fibers, reducing mitochondria disease, decreasing insulin resistance, decreasing plasma glucose, or decreasing weight, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist, are provided.

  本文提供了治疗、预防或改善与胰岛素和/或葡萄糖代谢紊乱、炎症性疾病、线粒体病、肌肉疾病或肺部疾病相关的一种或多种症状的方法，其中涉及给予一种PPARδ激动剂或含有PPARδ激动剂的制剂。在一种实施例中，所述疾病或症状被选自肌无力、炎症性血管疾病、帕金森和阿尔茨海默病、全身性炎症性疾病、肾脏缺血、炎症性风湿病和肺部炎症性疾病。在另一种实施例中，提供了通过给予PPARδ激动剂或含有PPARδ激动剂的制剂来增加氧化肌纤维、减少线粒体疾病、降低胰岛素抵抗、降低血浆葡萄糖或减轻体重的方法。
• USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES
  申请人：Cerenis Therapeutics S.A.

  公开号：EP2464349A2

  公开（公告）日：2012-06-20